Mantoux

MANTOUX TEST

1. MANTOUX DR. FIROZ A HAKKIM PG- 1 ST YR CHEST MEDICINE

2. TUBERCULIN SKIN TEST Detect infection with tubercle bacilli Low technology In expensive Easy to administer, read

3. Based on – infection with mycobacterium tuberculosis produces sensitivity to certain components called sensitins , which are contained in culture extracts called tuberculins

4. Used among children for detection of tuberculosis infection and as a supportive tool for diagnosis of tb disease Limited role in diagnosis of tb among adults living in areas where tb is highly endemic Used by epidemiologists for assesment of tb situation in community

5. History

6. Sir robert koch – produces a filtrate prepared from heat sterilized concentrated broth cultures of human tubercle bacilli Initialy prepared for treatment of Tb , but proved ineffective . Subcutaneous inoculation in a patient suffering from tb resulted in local reaction at inoculation site laid foundation of its use as diagnostic aid Was named OLD TUBERCULIN (OT)

7. Clement von pirquet in 1907 , observed that Tiny scratch with a little quantity of tuberculin resulted in a local reaction at the test site

8. Moro in 1908 announced the patch test Tuberculin was incorporated into an ointment that was smeared onto skin , with a piece of guaze over it

9. Charles mantoux developed the intradermal test, to be administered by injection as a measured volume ( mantoux test )

10. Other test – HEAF test – used a simple instrument that caused six spring loaded needles to pierce the skin with a drop of undiluted OT

11. TINE test – disposable multi puncture test where tuberculin was introduced into skin by puncture with four tines coated with dried tuberculin

12. ONLY MANTOUX TECHNIQUE WHICH ALLOWED QUANTITATIVE MEASUREMENT HAS STOOD THE TEST OF TIME, AND IS NOW THE STANDARD METHOD OF ADMINISTRATION OF TUBERCULIN SKIN TEST

13. Florence B. Seibert

14. Siebert in 1934 showed that active principle in tuberculin reaction was the protein fraction Made a preparation from heat concentrated synthetic medium OT by precipitation with trichloroacetic acid . It still contained lipopolysaccharides and nucleic acid Later precipitation achieved by ammonium sulphate to obtain a preparation with less nucleic acid and polysaccharide content termed PURIFIED PROTEIN DERIVATIVE (PPD)

15. ONE TUBERCULIN UNIT [TU] OF PPD WAS DEFINED AS THE ACTIVITY CONTAINED IN 0.02 MICROGRAM OF PPD

16. Statens serum institute , copenhagen produced a large batch of PPD in 1952 at behest of unicef and WHO, and was designated RT23 TWEEN 80 is added to prevent reabsorption of tuberculin to glass surface Seed lot of PPD RT23 is maintained by BCG VACCINE LABORATORY , GUINDY , CHENNAI. It is reconstituted and is supplied as ready to use preparation in isotonic buffer solution as 5ml vials, 0.1 ml corresponding to 1 TU.

17. Immunological basis Individuals infected with mycobacteium tuberculosis respond with delayed type hypersensitivity

18. Test site Injection of tuberculin Proliferation of sensitized T cell lymphocytes Cytokines & chemokines released Lymphocytes & monocytes attracted Increased permeability of local blood capillaries INDURATION at test site

19. Skin changes in TST Reaction include a delayed course reaching a peak more than 24 hrs after injection and an induration with occasional vesicilation and necrosis Delayed type hypersensitivity reaction peaks by 48 to 96 hours, with an area of erythmatous induration

20. Standard tuberculin skin test Standard test employs a single batch tuberculin ie PPD RT – 23 Dose – 0.02 microgram [ 1 TU ] of PPD RT -23 in 0.1 ml of the diluent with Tween 80

21. 2 TU of PPD RT – 23 is now recomended as the standard dose , based on a series of studies conducted in india It demonstrated equal sensitivity for 1 TU & 2TU in detecting true infection with mycobacterium tuberculosis. Available in 1TU/0.1ml, 2TU/0.1ml, 5TU/0.1ml and 10TU/0.1ml strengths.

22. 1TU/0.1ml 5TU/0.1ml

23. Earlier special glass syringes with a platinum needle was preferred for injection. These days disposable tuberculin syringes (1ml) are preferred.

24. Glass syringe 1 ml Plastic syringe

25. Storage Tuberculin vials – stored at 2-8 ° C and used before expiry period Avoid exposure to sunlight and heat Never freeze or keep at temp exceeding 20°C Vial once used may be re- used within a maximum of 48 hrs

26. Administration Administerd 2-4 inches below the elbow joint Place the forearm palm side up on a firm well lit surface Select an area free of barriers ( scars, sores ) to placing and reading Clean the area with an alcohol swab

27. Check expiry date on vial and ensure vial contains tuberculin (5TU per 0.1ml) Use a single dose tuberculin syringe with a ¼ to ½ inch 27 gauge needle with a short bevel Fill the syringe with 0.1 ml of tuberculin

28. Insert slowly , bevel up at 5- 15 degree angle After injection a tense pale wheal should appear over the needle Check the skin test- wheal should be 6-10 mm in diameter . If not repeat test at a site at least 2 inches away from original site Record information ( date, time of administration, injection site, location, lot number of tuberculin)

29. Educate the patient on the possible reactions to the TST (e.g., mild itching, swelling, irritation). Instruct patient not to rub, scratch or put an adhesive bandage or lotion on the test site. Schedule reading date and explain the importance of the patient returning for reading in 48 to 72 hours.

30. Reading (48-96 hrs) Visually inspect site under good light. Use fingertips to find margins of induration Mark induration by using fingertips as a guide for marking widest edges of induration across forearm Measure the induration ( not the erythema ) . Place the 0 ruler line inside left dot edge. Read ruler line inside right dot edge Record measurement of induration in mm Do not record as positive or negative Records made of bullae , vesicles, ulceration etc at test site

31. Interpretation

32. Adverse effects Some atopic individuals, develop an urticarial wheal, which may dissapear within minutes. Occurence of such an allergic reaction does not signify the presence of TB. Systemic allergic reactions seldom occur Formation of vesicles, bullae , lymphangitis , ulceration or necrosis in a proportion of children indicates high degree of tuberculin sensitivity.

33. Skin sensitivity to tuberculin Persons with sensitivity to tuberculin are called ‘Reactors’. Not all reactors are infected with tubercle bacilli. Sensitivity to tuberculin may oocur due to infection with environmental mycobacteria BCG Vaccination Infection with Mycobacterium tuberculosis

34. Infection with environmental mycobacteria Sensitivity induced by them cross-reacts with tuberculin and is known as ‘Non Specific Sensitivity’ (NSS). sensitivity induced by these results in smaller reactions. Distinction from true infection is not always very clear. Highly prevalent in most parts of India .

35. BCG Vaccination Sensitivity may vary from very weak to about the same level as natural infection. Depends on strength of vaccine used, handling, administration, and time interval between vaccination and testing. Generally peaks at 10 weeks then begin to wane. Under UIP in India, a reduced dose of 0.05 ml of Danish 1331 strain is administered .

36. About 70% of children upto 9 yrs of age with a BCG scar elicited either no rection or <10mm to 1 TU PPD with Tween 80. It may be inferred that the BCG induced sensitivity is generally weaker than that of infection with tubercle bacilli. Weak sensitivity does not imply that vaccination is ineffective.

37. Infection with Mycobacterium tuberculosis Most individuals harbouring TB infection usually elicit a larger reaction to tuberculin The probability of true positives increases as the reaction size increase s Probability is also increased in the presence of history of contact with a sputum smear positive case of TB.

38. False positive reactions Infection with environmental mycobacteria . BCG vaccination. Repeat testing. Testing with high dose of tuberculin. Reading errors. Needle injury.

39. False negative reactions Non significant reaction does not always exclude the presence of TB infection or disease. Most common reasons being : Improper storage Poor technique Other reasons : Immunosupression Disseminated TB Undernutrition

40. Hodgkin’s Malignancy Sarcoidosis HIV – AIDS Vaccination with live virus vaccines Acute viral infections Window period Infants < 3months ( immature immune system) Old age Cutaneous anergy Supression due to live virus vaccines appears after 48 hrs of vaccination and start waning 4-6 wks later.

41. Anergy Anergy refers to failure to mount a full immune response against a target. Term ‘ANERGY’ was coined by Von Pirquet Commonly used antigens for anergy panel contain trychophyton , candida , etc Anergic patients are more likely than immunologically intact patients to present with noncavitory TB.

42. In sarcoidosis patients, anergy to tuberculin can be restored by concurrent administration of hydrocortisone. This paradoxical reaction presumably also occurs in TB patients who have been desensitized for tuberculin.

43. Reversion, Conversion and Booster Phenomenon Reversion: In elderly & many adults, significant reactions to tuberculin declines with age. Estimated to occur at a rate of 5% per yr. Attributed to waning of CMI or loss of lymphocyte blastogenic capacity in elderly.

44. Booster phenomenon Boosting of the size of the second test by the small amount of tuberculin injected for the first test. Results from ‘recall’ of the sensitivity. To avoid this, repeat test should be given at a different site within one week of the first test. Boosting effect was observed when test repeated after 2 months ,not when repeated after 18 months.

45. Conversion Simple tuberculin conversion from a non significant reaction at first test to a significant reaction at a subsequent test. Larger increase in reaction size (10mm or more) correlates better with the risk of developing TB. Other causes can be boosting effect, infection with environmental mycobacteria in the intervening period. For detection of new infections, there should be a significant increase in reaction size (14mm or more) in the subsequent test, one-and-half to 3 yrs apart.

46. Interpretation in HIV patients All HIV seropositive individuals should be assessed for active TB. Once active TB is excluded, TST is done as soon as possible. Reliability of TST decreases as CD4+ T-Cell count diminishes, espp . To < 200/ cmm . As the prob. of significant induration indicative of TB infection is significantly lower in HIV-infected persons, a lower cut-off point is advised.

47. Irrespective of the test results, patients with evidence of old healed TB in CXR or past H/O active TB and a significant reation to TST may be considered infected for all practical purposes. TST should never be the sole criteria for diagnosing TB.

48. Interpretation in sarcoidosis TST in patients with sarcoidosis has a high specificity but poor sensitivity for TB. A – ve TST in general poulation is a sensitive test for sarcoidosis . A + ve TST in patients suspected of havin sarcoidosis is a specific test for TB, and is an absolute indication for a thorough work-up for TB.

49. Epidemiological use Tuberculin surveys are carried out among young children as the results obtained reflect relatively recent situation. Prevalence and Average Annual Risk of Infection (ARI) are calculated. ARI is defined as the avg. prob. of acquiring new TB infection over the course of one year. ARI reflects the overall impact of TB prevalence in a community and the efficiency of TB control activities.

50. Newer tuberculins Further attempts are being made to develop newer, more species-specific tuberculins . One of the improvisations is to avoid heating to prevent protein denaturation of PPD. Electrophoresis and Chromatography. T-1327 and T-1456 are under progress.

51. Interferon gamma release assays ( IGRA) In vitro assays that detect the presence of CMI towards M. tb -specific antigens. These include the early secretory antigenic target-6 (ESAT-6), culture filtrate protein 10 (CFP-10), and the TB7.7 antigens. The antigens in IGRAs are absent in most of NTM as well as in BCG strains.

52. Available methods : Quantiferon - TB Gold assay (ELISA based) Quantiferon - TB Gold IN Tube assay(ELISA based) T-SPOT TB assay (ELISPOT based)

53. Advantages of IGRA’s Higher specificity then TST. Less cross reactivity with BCG vaccination and NTM infection Less inter-reader variations. No boosting phenomenon. Fewer patient visits.

54. Disadvantages of IGRA’s A negative IGRA does not rule out active TB or LTBI. IGRAs are not able to differentiate LTBI from active TB. In high-TB incidence countries, there is no added value in using IGRAs to diagnose LTBI, as the focus of prevention and control is to identify and treat active cases.

55. In presence of immunosuppression , a – ve IGRA should not preclude further investigations or treatment if clinical suspicion is high. Technically more demanding. Higher cost.

56. Conclusion Tuberculin test have stood the test of time and is still widely used for over a century for detecting the infection with TB and when used wisely, has promising results. For now, it is probably a good strategy to keep both IGRA’s and TST on the LTBI diagnostic menu, and select the appropriate test based on population, purpose of testing and the available resources.

57. REFERENCES SHARMA TOMANS INTERNET